Q2 2026 Exelixis Inc Earnings Call Transcript
Key Points
- Exelixis Inc (EXEL) reported strong Q2 2026 financial results with total revenues of approximately $629 million and GAAP net income of $212 million, reflecting solid operational performance.
- The cabozantinib franchise continues to grow, with US net product revenues up 10% year-over-year to $573 million and global revenues up 13% to $806 million, driven by strong RCC and NET market share gains.
- Zanzalintinib is advancing well, with the STELLAR-303 NDA under FDA review (PDUFA in December 2026) and six additional pivotal trials progressing, including STELLAR-304 expected to read out in H2 2026.
- The company is executing on its strategic expansion, with new trials like STELLAR-316 (adjuvant CRC) and STELLAR-202 (squamous NSCLC) set to initiate, and expansion cohorts in bladder and prostate cancer showing early promise.
- Exelixis Inc (EXEL) maintains strong financial discipline, reducing R&D expense guidance by $50 million while keeping free cash flow essentially unchanged, and continues to return capital to shareholders via a $750 million buyback program.
- The NET franchise is gaining traction, with CABOMETYX achieving over 45% new patient market share in the second-line plus setting, positioning it as the leading oral therapy and a key growth driver.
- Exelixis Inc (EXEL) lowered its full-year 2026 revenue guidance by $50 million at the midpoint, reflecting a more gradual ramp in the NET indication due to slower patient kinetics and indolent disease characteristics.
- The STELLAR-303 trial's non-liver metastasis subgroup failed to achieve statistical significance on overall survival, raising potential concerns about the robustness of the overall data despite the ITT population being positive.
- The NET market ramp is slower than expected, with patients often taking treatment breaks or delaying subsequent therapy, which could limit near-term revenue growth from this indication.
- The company faces potential competitive and regulatory risks, including the tentative approval of ANDAs for generic versions of cabozantinib, which could impact future market exclusivity despite existing agreements.
- Enrollment in the STELLAR-304 trial took longer than originally projected, and the company remains cautious about data timing, with results still expected in H2 2026 but subject to event rate variability.
- The launch of zanzalintinib in CRC is pending FDA approval, and any label restrictions or subgroup limitations could constrain commercial uptake, especially in the third-line plus setting.
Good day, ladies and gentlemen, and welcome to the Exelixis second-quarter 2026 financial results conference call. My name is Kathleen, and I will be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Mr. Andrew Peters, Senior Vice President of Strategy and Investor Relations. Please proceed.
Thank you, Kathleen, and thank you all for joining us for the Exelixis' second quarter 2026 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; Dana Aftab, our Executive Vice President of Research and Development; and P.J. Haley, our Executive Vice President of Commercial, who will review our progress for the second quarter 2026 ended June 30, 2026.
During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
